Contrasting Achillion Pharmaceuticals (NASDAQ:ACHN) and Ovid Therapeutics (NASDAQ:OVID)

Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Valuation & Earnings

This table compares Achillion Pharmaceuticals and Ovid Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Achillion Pharmaceuticals $15.00 million 41.62 -$70.27 million ($0.51) -8.82
Ovid Therapeutics N/A N/A -$51.98 million ($2.11) -0.91

Ovid Therapeutics has lower revenue, but higher earnings than Achillion Pharmaceuticals. Achillion Pharmaceuticals is trading at a lower price-to-earnings ratio than Ovid Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

79.3% of Achillion Pharmaceuticals shares are held by institutional investors. Comparatively, 31.7% of Ovid Therapeutics shares are held by institutional investors. 4.6% of Achillion Pharmaceuticals shares are held by company insiders. Comparatively, 29.8% of Ovid Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Achillion Pharmaceuticals has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Achillion Pharmaceuticals and Ovid Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Achillion Pharmaceuticals 1 0 1 0 2.00
Ovid Therapeutics 0 0 5 0 3.00

Achillion Pharmaceuticals presently has a consensus target price of $2.50, indicating a potential downside of 44.44%. Ovid Therapeutics has a consensus target price of $15.50, indicating a potential upside of 711.52%. Given Ovid Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Ovid Therapeutics is more favorable than Achillion Pharmaceuticals.

Profitability

This table compares Achillion Pharmaceuticals and Ovid Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Achillion Pharmaceuticals N/A -25.19% -24.25%
Ovid Therapeutics N/A -101.57% -86.47%

Summary

Ovid Therapeutics beats Achillion Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate, which has completed Phase 1b/2a trial for rare epileptic encephalopathies. The company has collaboration agreement with Takeda Pharmaceutical Company Limited; and a license agreement with H. Lundbeck A/S. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

CSat Investment Advisory L.P. Increases Stake in Humana Inc
CSat Investment Advisory L.P. Increases Stake in Humana Inc
CSat Investment Advisory L.P. Boosts Stake in PepsiCo, Inc.
CSat Investment Advisory L.P. Boosts Stake in PepsiCo, Inc.
CSat Investment Advisory L.P. Boosts Stake in Alibaba Group Holding Ltd
CSat Investment Advisory L.P. Boosts Stake in Alibaba Group Holding Ltd
CSat Investment Advisory L.P. Cuts Position in Nasdaq Inc
CSat Investment Advisory L.P. Cuts Position in Nasdaq Inc
CSat Investment Advisory L.P. Sells 621 Shares of General Mills, Inc.
CSat Investment Advisory L.P. Sells 621 Shares of General Mills, Inc.
Line Corp  Shares Sold by CSat Investment Advisory L.P.
Line Corp Shares Sold by CSat Investment Advisory L.P.


© 2006-2019 Ticker Report